About the Webinar
There’s an exciting landscape of biotherapeutics and novel modalities for the treatment of oncology indications, but their unique properties present challenges, such as determining FIH starting dose. In this webinar, Piet van der Graaf, PharmD, PhD, FBPhS, SVP and Head of QSP at Certara will discuss:
- The background of bispecific antibodies and opportunities for clinical pharmacology and quantitative systems pharmacology (QSP), such as understanding and predicting Cytokine Release Syndrome (CRS)
- Current industry best practices about dose optimization, approaches for FIH starting dose selection, selection of MIDD approaches, and pivoting oncology programs to other indications
- Case study examples that demonstrate how we collaborated with our partners to justify the selection of a higher FIH starting dose, limiting the number of patients receiving subtherapeutic doses and supporting dose optimization and selection for oncology therapies.